Company intelligence / Profile preview
CO.DON GmbH
Leipzig, Germanycodon.de ↗
- Ownership
- Private
- Development stage
- Commercial
01
Overview
CO.DON has EU-wide marketing authorization for its product Spherox for the regenerative treatment of knee cartilage defects. Over 19,000 patients have been treated with CO.DON products since 1997[5][6].
- Therapeutic areas
- Rheumatology
- Modalities
- Cell-based therapiesAutologous cell therapiesCartilage cell implants
- Industry
- Biotech
02
Drug pipeline
1 assetBeyond the preview
Go deeper on CO.DON GmbH.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on CO.DON GmbH.